# Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression

> **NCT01401192** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 304 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Gemcitabine plus cisplatin
- **DRUG:** pemetrexed plus cisplatin
- **DRUG:** pemetrexed plus cisplatin
- **DRUG:** Gemcitabine plus cisplatin

## Key facts

- **NCT ID:** NCT01401192
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-07
- **Primary completion:** 2013-12
- **Final completion:** —
- **Target enrollment:** 304 (ESTIMATED)
- **Last updated:** 2011-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01401192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01401192, "Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01401192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*